Cargando…

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

Detalles Bibliográficos
Autores principales:	Bleckmann, Annalen, Dierks, Sascha, Schildhaus, Hans-Ulrich, Hellige, Niels, Bacher, Ulrike, Trümper, Lorenz, Wulf, Gerald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782442/ https://www.ncbi.nlm.nih.gov/pubmed/32193631 http://dx.doi.org/10.1007/s00277-020-03974-y

Ejemplares similares

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Identification of effective natural PIK3CA H1047R inhibitors by computational study
por: Liu, Naimeng, et al.
Publicado: (2021)

Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
por: Gkeka, Paraskevi, et al.
Publicado: (2014)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R
por: Zeng, Li, et al.
Publicado: (2023)

Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
por: Yuan, W, et al.
Publicado: (2013)

Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature
por: Oh, Kei Shing, et al.
Publicado: (2023)

DMBA induced mouse mammary tumors display high incidence of activating Pik3ca(H1047) and loss of function Pten mutations
por: Abba, Martín C., et al.
Publicado: (2016)

Highly sensitive detection of the PIK3CA(H1047R) mutation in colorectal cancer using a novel PCR-RFLP method
por: Li, Wan-Ming, et al.
Publicado: (2016)

A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
por: Kalofonou, Melpomeni, et al.
Publicado: (2020)

NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CA(H1047R) homozygosity in pluripotent stem cells
por: Madsen, Ralitsa R., et al.
Publicado: (2021)

Physiological Levels of Pik3ca (H1047R) Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors
por: Tikoo, Anjali, et al.
Publicado: (2012)

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
por: Meyer, D S, et al.
Publicado: (2013)

Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
por: Lee, Kang-Hoon, et al.
Publicado: (2019)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis
por: Yuan, Wenlin, et al.
Publicado: (2019)

1047 proverbios del mundo : divertidos, sabios y profundos /
Publicado: (1997)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

Dissecting the molecular pathogenisis of Burkitt lymphoma
por: Kube, D, et al.
Publicado: (2009)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

“SpezPat”- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians’ understanding of non-small cell lung cancer patients’ end-of-life decisions
por: Koenig, Julia Felicitas Leni, et al.
Publicado: (2022)

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
por: Coelho, H., et al.
Publicado: (2017)

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis
por: Shumilov, Evgenii, et al.
Publicado: (2022)

1047. Impact of Indication for Antibiotic Orders on Pharmacist Interventions
por: Scardina, Tonya, et al.
Publicado: (2019)

Calling large indels in 1047 Arabidopsis with IndelEnsembler
por: Liu, Dong-Xu, et al.
Publicado: (2021)

SG-APSIC1047: Patient instrument tracking system
por: Sirijindadirat, Nanthipha, et al.
Publicado: (2023)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways
por: Candido, Saverio, et al.
Publicado: (2022)

Multiple cranial nerve palsies in immunodeficiency subtype of Burkitt lymphoma
por: Ali, Abbas, et al.
Publicado: (2018)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
por: Wang, Zhiyong, et al.
Publicado: (2014)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_73hmuiiurg93favp37rtth4egb